Early in 2026, a Jinxin Fertility Group quality team led by Professor Li Yuan visited the reproductive centre for its annual review.
The assessment used case reviews, process checks and staff interviews, alongside a presentation of clinical quality data and improvement work.
The report describes individualized clinical pathways, informed consent and ongoing patient communication. Laboratory measures included environmental monitoring, double-checking specimen identities and process traceability.
The review identified areas for further improvement in clinical and laboratory quality management. It did not provide a current Wuhan-specific success rate for publication on this website.
JINXIN · CARE CONTINUESBack to News